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Abstract 53 
Immune checkpoint inhibitors have led to considerable therapy improvement in 54 
cancer patients. Autoimmune side effects including skin reactions are frequently 55 
observed. In melanoma those include rash and vitiligo and were shown to be 56 
associated with a prolonged overall survival. Little is known about skin reactions in 57 
NSCLC patients during immunotherapy. 58 
Here, we retrospectively investigated immune-related adverse skin reactions (irAEs) 59 
in 40 patients with metastatic non-small cell lung cancer (NSCLC) treated with the 60 
anti PD-1 antibody nivolumab. 7 out of 40 patients (17%) developed an irAEs.  61 
Skin irAEs correlated with tumor responses in 5 of 12 responders (42%) as 62 
compared to 2 of 27 non-responders (7%). Histologically, scaly plaques showed 63 
dermatitis consisting mainly of lymphocytes. 64 
We observed a positive correlation between skin irAEs and tumor responses in 65 
patients with NSCLC treated with nivolumab. Patterns of lymphocytic skin infiltration 66 
differed depending on the histological tumor subtype (adenocarcinoma versus 67 
squamous cell carcinoma NSCLC). 68 
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Introduction 79 
Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung 80 
cancers and can be divided into two major histological subtypes: adenocarcinoma 81 
(AC) and squamous cell carcinoma (SCC). Standard first-line treatment of metastatic 82 
disease consists of platinum-based chemotherapy. In selected molecular-defined 83 
subgroups the first-line therapy is a targeted therapy using tyrosine kinase inhibitors 84 
(TKI). 1  85 
The introduction of immunotherapy has significantly improved therapy outcome. Two 86 
phase III trials with the anti-PD1 (anti-programmed death 1 receptor) antibody 87 
nivolumab led to its approval in 2015 after it had been approved for metastatic 88 
melanoma in 2014. 2-5  89 
PD1-checkpoint inhibitors block the interaction between PD1-receptors on T-cells 90 
and their ligand PD-L1. Blocking PD1-receptors enhances T-cell response against 91 
cancer cells. 6 In turn, activated T-cells can cause autoimmune-mediated side 92 
effects, such as skin rash, colitis, hepatitis or pneumonitis. These are generally 93 
manageable and reversible in most cases. Rash and pruritus are frequent immune-94 
related dermatologic adverse reactions (skin irAEs) during immunotherapy, which 95 
have been reported to occur in up to 25 % of melanoma patients. 4, 5, 7, 8 Toxicity data 96 
for anti-PD1 approval in NSCLC reports skin irAEs in approximately 10% of patients 97 
2, 3, 9, but as of recently higher rates have emerged. 10, 11 Grading of toxicity is 98 
commonly classified according to Common Terminology Criteria for Adverse Events 99 
(CTCAE version 4.0). Management of skin irAEs includes symptomatic treatment 100 
with antihistamines and topical steroids, but may be complemented with systemic 101 
immunosuppression in severe cases. 12 Previous data strongly suggest that skin 102 
irAEs under anti-PD1 therapy are associated with increased overall survival (OS) and 103 
may serve as a parameter to predict a better therapy response. 13, 14  104 
 5 
The aim of this study is to i) characterize skin irAEs in patients with advanced lung 105 
cancer treated with nivolumab and ii) to specify the pattern of T-cell infiltration in 106 
biopsies of these skin lesions. 107 
 108 
 109 
Materials and Methods 110 
Assessing tumor response to therapy with nivolumab and skin irAEs  111 
After approval by the local ethics committee (EKSG Nr. 16/059) and in accordance 112 
with the Declaration of Helsinki Principles, we retrospectively analyzed patients with 113 
metastatic NSCLC treated with nivolumab (Opdivo®, Bristol-Meyers Squibb, SA). 114 
Treatment was initiated between January 2015 and February 2016 within an early 115 
access program at the Cantonal Hospital St. Gallen (Switzerland). Patients had at 116 
least one treatment cycle with the standard dose of 3 mg/kg i.v. over 60 minutes 117 
every two weeks. Tumor response was evaluated using computed tomography (CT) 118 
and was categorized as progressive disease (PD), stable disease (SD) and partial 119 
remission (PR) according to RECIST criteria 1.1. 16 We further assessed results of 120 
skin examinations that had been performed during patient visits and classified skin 121 
irAEs according to clinical dermatological criteria.  122 
 123 
Immunohistochemistry analysis  124 
Histology of punch biopsies from untreated skin rash was available from 4 patients, 125 
of which 2 had SCC and 2 had AC. Biopsies of the SCC patients were taken from the 126 
right forearm and right lower limb and of the AC patients from the right cheek and left 127 
lower limb (one each, respectively).  All punch biopsies had been performed by a 128 
dermatologist. Histopathological analyses were conducted independently by a 129 
pathologist and a dermatopathologist. From each representative paraffin-embedded 130 
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skin block four microns-thick sections were obtained for HE and 131 
immunohistochemistry (IHC) staining (CD3, CD4 and CD8). For each sample we 132 
determined lymphocyte counts in the epidermis and dermis per 1mm2 (= 4 random 133 
high power fields).  134 
 135 
 136 
Results 137 
Tumor response and skin irAEs in NSCLC under nivolumab therapy  138 
We identified 41 patients treated with at least one single dose of nivolumab. One 139 
patient was excluded because consent was refused. Patient age ranged from 46 to 140 
88 years (mean 65 years). 22 (55%) were male and 18 (45%) female (Table 1). On 141 
average, the 40 patients were treated with 7 cycles, ranging from 1 to 25 cycles. The 142 
interval between treatment initiation and appearance of a skin irAE was 3 cycles. 143 
23 (57%) of our patients had ACs, 14 (35%) SCCs and in 3 (8%) the tumor displayed 144 
features of both subtypes (mixed subtype). 27 (67%) showed disease progression 145 
under nivolumab therapy. We were unable to assess disease progression in one 146 
individual because the patient had died due to ileus before a re-staging could be 147 
performed.  148 
7 (17%) developed a skin irAE under treatment. All skin reactions were classified 149 
grade I or II (CTCAE 4.0). In this subpopulation 4 (57%) were scaly plaques (Figure 150 
1A/B) and 3 (43%) intense pruritus without visible skin lesions. Only 2 (29%) with 151 
skin irAEs had PD, as opposed to all patients, where the majority had PD. 152 
Furthermore, skin irAEs correlated with tumor responses in 5 of 12 responders (42%) 153 
as compared to 2 of 27 non-responders (7%).  154 
 155 
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Immune infiltrate patterns of skin rash under nivolumab therapy correlates with 156 
NSCLC subtype  157 
Immunohistochemistry of the skin biopsies showed that the distribution of CD3+ T-158 
cells in the inflammatory skin infiltrate was dependent on the cancer subtype (Figure 159 
1F/G). We observed an analogous cell distribution pattern among cytotoxic CD8+ T-160 
cells. In patients with SCCs the lymphocyte infiltrates were more prominent above 161 
the basal cell membrane whereas patients with ACs showed CD8+ T-cell infiltrates 162 
more accentuated towards the dermis (Figure 2A-D). Quantification of the T-cell 163 
infiltrates further supported this observation: the ratios of CD8+ T-cells found in the 164 
epidermis compared to all CD8+ T-cells of two patients with SCCs were 22% and 165 
44%, respectively, while in two patients with ACs the ratios were 3% and 10%, 166 
respectively (Figure 2A-D).   167 
 168 
 169 
Discussion 170 
Autoimmune-mediated side effects affecting different organs are known to occur 171 
during treatment with immunotherapy. In NSCLC patients treated with nivolumab skin 172 
eruptions and pruritus have been reported in approximately 10% or higher.  2, 3, 9-11 173 
This was also reflected by our study. Several authors reported higher numbers of 174 
skin irAEs in melanoma patients under nivolumab treatment. 4, 5, 7, 8  175 
An association between appearance of skin irAEs and overall survival in melanoma 176 
has been reported. 13-15, 17 Similarly, our data suggests an association between skin 177 
irAEs and tumor response. The histological analysis of the rashes on the one hand 178 
allowed us to rule out clinical differential diagnoses of eczema and psoriasis and on 179 
the other hand revealed that the rashes were characterized by an inflammation rich 180 
in CD3+ T-lymphocytes. Immunophenotypisation showed analogous lichenoid 181 
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patterns among rashes with SCC-patients. They displayed distinct epidermotropic 182 
inflammatory infiltrates consisting mainly of cytotoxic CD8+ T-cells. Civatte bodies 183 
(damaged basal keratinocytes) suggest that these lymphocytes induce keratinocyte 184 
death. From these findings we deduct that the skin of these patients harbored auto-185 
immune T-cells that were activated and attacked healthy keratinocytes. It is further 186 
possible that tumor-specific T-cells, activated by anti-PD1 treatment, migrated to the 187 
skin. Since T-cells can migrate and scan antigens presented by MHC-I molecules on 188 
all body cells, they can recognize the same antigen at any body site. It is possible 189 
that keratinocytes express antigens that are identical or very similar to those of the 190 
tumor, known as antigen sharing or as molecular mimicry, respectively. 18 In our point 191 
of view, antigen sharing can presently be considered the most likely cause, as lung 192 
SCCs and keratinocytes both produce similar proteins including several cytokeratins. 193 
19 In  contrast, the histology of skin rashes of AC patients showed inflammation with 194 
lymphocytes located predominantly below the basal cell membrane within the dermis, 195 
which contains glandular structures (e.g. eccrine sweat glands). Those may share 196 
antigens with lung ACs.   197 
Limitation of the study was the small sample size of 40 patients. One needs to keep 198 
in mind that immunotherapy for treating NLCSCs has only recently been approved 199 
and was provided through the early access program. We are confident that the 200 
recent approval now enables broader access to immunotherapy, which will allow our 201 
findings to be compared to future investigations from larger sample sizes.     202 
In conclusion, our results suggest that the tissue tropism of lymphocytes in skin irAEs 203 
may be more specific than previously known, opening new opportunities for 204 
elucidating the underlying molecular mechanisms. 205 
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 300 
Figure legends: 301 
 302 
Figure 1. a. Skin rash under nivolumab in a patient with squamous cell carcinoma 303 
(SCC) of the lung or b. adenocarcinoma (AC) of the lung. c. Histopathology shows 304 
an inflammatory infiltrate migrating into the epidermis in SCC patients (hematoxylin 305 
eosin (HE), 100x). d. Apoptotic keratinocytes, also called Civatte bodies, are visible 306 
in SCC patients (HE, 200x). e. The infiltrate does not seem to migrate in AC patients 307 
(HE, 100x). f. Immunohistochemistry shows that the inflammation consists mainly of 308 
lymphocytes in both SCC (CD3, 100x) and g. AC (CD3, 100x) patients. The basal 309 
cell membrane is outlined in red.  310 
 311 
Figure 2. a.b. Immunohistochemistry with a CD8 stain of skin rash of 2 SCC patients 312 
(CD8, 100x) and c.d. 2 AC patients (CD8, 100x). The migration of the inflammation 313 
appears to differ among tumor subtypes. The number in the upper right corner of 314 
each panel indicates the percentage of CD8+ T-cells in the epidermis compared to 315 
the total of CD8+ T-cells of 4 high-power fields. They illustrate that the relative CD8+ 316 
T-cell count in the epidermis is greater among 2 SCC patients than among 2 AC 317 
patients. 318 
 319 
 320 
  321 
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Table 1. Patient characteristics.  322 
Parameter  
 
  
Patient number 
 
 40 
Age (years) 
 Mean 
Range 
65.5 
46 - 88 
Gender 
 Male 
Female 
22 
18 
Histological type 
 Adenocarcinoma 
Squamous cell carcinoma 
Mixed type 
23 
14 
3 
Nivolumab cycles 
 Mean 
Range 
7 
1 - 25 
Nivolumab cycles until 
adverse skin reaction 
 Mean 
Range 
3 
2 - 8 
Type of adverse skin 
reaction 
 Plaques 
Pruritus 
4 
3 
Tumor response in patients 
with adverse skin reaction 
 Response 
No response 
5 
2 
 323 
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Table 2.  Clinical presentation and histology of 4 patients 
 
aNSCLC: non-small cell lung cancer 
bAC: adenocarcinoma 
cSCC: squamous cell carcinoma 
Patient Gender, age in years 
Onset (after 
cycles/days) NSCLC
a Clinical presentation Histology 
1 m; 69 2/15 SCCb 
Focal plaques with thick squamae 
on the extremities, with burning 
sensation, no mucosal 
involvement. 
Lichenoid dermatitis with interface-
component at the dermo-epidermal 
junction and CD8+ cell infiltrate in 
the epidermis and dermis. 
 
 
2 m; 68 2/37 SCC 
Focal plaques with thick squamae 
on the extremities, mild pruritus 
and burning, no mucosal 
involvement. 
Lichenoid dermatitis with interface-
component at the dermo-epidermal 
junction. CD8+ cell infiltrate visible 
in the epidermis, with apoptotic 
keratinocytes, and the dermis. 
 
3 f; 86 1/7 ACc 
Focal scaly plaques on the 
extremities with pruritus, no 
mucosal involvement. 
 
Spongiotic dermatitis with 
accumulation of CD8+ T-cells below 
the basal cell membrane, sparse 
affection of epidermis. 
 
4 m; 59 8/111 AC 
Focal erythematous plaques with 
fine scaling on the upper face, no 
mucosal involvement. 
 
Lymphocytic infiltrate with 
accentuation in the deep dermis. 
Sparse interface component with 
sporadic vacuolization of basal 
keratinocytes. 
 
